重组杆状病毒细小VP2蛋白40L生物反应器放大工艺研究

Scale-up Process Optimization for Recombinant PPV-VP2 Protein Production Using Baculovirus Expression System in 40L Bioreactor

研究了Sf9细胞生产重组杆状病毒细小VP2蛋白在机械搅拌式生物反应器(STR)中从3L至40L的放大工艺。首先在3L反应器中,通过DO和搅拌转速的优化,使反应器中的VP2蛋白HA效价不低于摇瓶结果。在40L反应器放大时,温度、p H、DO保持不变,根据输入搅拌功率、体积溶氧系数和叶尖线速度等工程参数的计算,得到了该反应器的合理搅拌转速,最终HA效价测定结果与小罐一致。豚鼠免疫试验证实,反应器中表达的VP2蛋白制成疫苗,与HN2011灭活苗及商品化灭活疫苗相比,抗体水平上升较快且高于传统灭活苗。

The focuses are on the scale-up of a Sf9 cell line to produce recombinant porcine parvovirus（ PPV） VP2 protein expression using baculovirus/insect expression system from the initial 3-L bench scale to the40-L scale. In 3 L bioreactor,HA titer of VP2 protein side-by-side comparison of shake flask by optimization of DO and Agit. The operational parameters of temperature,DO,and p H for large vessels were set at the same values as those of 3-L bioreactor. Appropriately applying the calculated results to power input per volume,oxygen transfer coefficient and tip speed,resulted in successful scale-up of agitation speed for the large bioreactors. By HA titer analysis,VP2 protein had identical haemagglutinating activity comparison of 3-L. By guinea pig immunization test,It is found that recombinant VP2 subunit vaccine can be induced high level antibody reaction,and immune with recombinant VP2 subunit vaccine was faster than classical inactivated PPV vaccine.